Immatics
patient flow so | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
15 of 75
Related slides by other companies
GH Research
Investor Presentation
March 2023
phase single dose efficacy | GH Research
GH Research
Investor Presentation
March 2023
and observed improved outcome in phase phase single dose | GH Research
Ocuphire Pharma
Investor Presentation
May 2023
profile overview well tolerated oral dose up to day twice daily dosing progression of diabetic minimal ocular side effects ire cine | Ocuphire Pharma
ATAI
Investor Presentation
January 2024
phase is a randomized double blind single dose study in moderate to severe patients | ATAI
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights